SEC Form 4 · accession 0001104659-26-073567
Apogee Therapeutics, Inc. · APGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Thomas Henderson
Officer — Chief Executive Officer · Director
Period of report
Jun 10, 2026
Accepted (ET)
Jun 12, 2026 · 5:05 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001974640
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 10, 2026 | S | 6,770 | $82.21 | D | 1,109,217 | D | |
| Common StockF3 | Jun 10, 2026 | S | 7,654 | $82.78 | D | 1,101,563 | D | |
| Common StockF4 | Jun 10, 2026 | S | 1,080 | $84.18 | D | 1,100,483 | D | |
| Common StockF5 | Jun 10, 2026 | S | 1,577 | $85.19 | D | 1,098,906 | D | |
| Common StockF6 | Jun 10, 2026 | S | 2,305 | $86.27 | D | 1,096,601 | D | |
| Common StockF7 | Jun 10, 2026 | S | 614 | $86.89 | D | 1,095,987 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.
- F2The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.57 to $82.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- F3The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.57 to $83.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.595 to $84.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F5The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $84.71 to $85.665, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F6The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.74 to $86.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F7The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.835 to $87.165, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.